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Tissue-type plasminogen activator (tPA) a serine protease is constituted of five functional
domains through which it interacts with different substrates, binding proteins, and
receptors. In the last years, great interest has been given to the clinical relevance
of targeting tPA in different diseases of the central nervous system, in particular
stroke. Among its reported functions in the central nervous system, tPA displays both
neurotrophic and neurotoxic effects. How can the protease mediate such opposite
functions remain unclear but several hypotheses have been proposed. These include an
influence of the degree of maturity and/or the type of neurons, of the level of tPA, of its
origin (endogenous or exogenous) or of its form (single chain tPA versus two chain tPA).
In this review, we will provide a synthetic snapshot of our current knowledge regarding
the natural history of tPA and discuss how it sustains its pleiotropic functions with focus
on excitotoxic/ischemic neuronal death and neuronal survival.
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THE NATURAL HISTORY OF tPA
Morgagni (1761) noted that the blood of patients who died suddenly was not completely
coagulated. Denis (1838) observed the spontaneous dissolution of blood clots. Fifty years later,
Denys and de Marbaix (1889) postulated the existence of an endogenous ﬁbrinolytic enzyme.
Accordingly, Hedin (1903) revealed a proteolytic activity in serum globulin fraction, later identiﬁed
as the fraction containing a precursor of plasmin. Christensen and Macleod (1945) proposed that
this inactive circulating precursor, named plasminogen, could be activated by bacterial extracts
like streptokinase. Macfarlane and Biggs (1948) completed the description of the plasminogen
activation cascade. In parallel, Conradi (1902) identiﬁed tPA, at this time named ﬁbrikinase, in
diﬀerent organs), later characterized to mediate ﬁbrinolysis (Fleisher and Loeb, 1915; Astrup and
Permin, 1947; Astrup and Stage, 1952). tPA was then puriﬁed from human vessels and uterus in
Binder et al. (1979), Rijken et al. (1979) and in larger amounts from Bowes melanoma cell line
allowing its biochemical characterization (Collen et al., 1982; Collen and Lijnen, 2009). Pennica
et al. (1983) succeeded in cloning and expressing recombinant tPA, providing the primary structure
of tPA. tPA is a protein of 527 amino-acids including three glycosylation sites and 17 disulﬁde
bridges (Pennica et al., 1983). Collen and Lijnen (1991) then provided evidence that tPA could
facilitate the dissolution of blood clots by inducing the degradation of ﬁbrin in a plasminogen-
dependent manner. tPA is now used in the clinic to promote ﬁbrinolysis, especially at the acute
phase of ischemic stroke either alone (NINDS, 1995) or combined with thrombectomy (Campbell
et al., 2015; Goyal et al., 2015).
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In addition to this ﬁbrinolytic function at the origin of its
discovery, an increasing number of studies have since the mid-
90s, discovered functions of tPA within the brain parenchyma.
In particular, tPA is believed to control neuronal fate during
several CNS disorders, including multiple sclerosis, Alzheimer’s
disease, and stroke. The aim of this review is to summarize and
discuss structure-function studies related to the inﬂuence of tPA
on neuronal death and survival.
tPA OR tPAS?
The mature form of tPA is a mosaic protein of ﬁve distinct
modules, which, from its N-terminal end to its C-terminal end,
are: a ﬁnger domain (F), an epidermal growth factor-like domain
(EGF), two kringle domains (K1 and K2), and a serine protease
proteolytic domain (SP). The ﬁnger domain is involved in tPA
binding to ﬁbrin and is necessary to promote ﬁbrinolytic activity
at low plasminogen activator concentrations (Larsen et al., 1988).
In the brain, other functions attributed to the ﬁnger domain
include its ability to cross the blood–brain barrier (Benchenane
et al., 2005), its astrocytic clearance (Cassé et al., 2012) and some
of its signaling pathways (Siao and Tsirka, 2002; Pineda et al.,
2012). The EGF-like domain shows homology with EGF. Both
the trophic and mitogenic functions of tPA have been attributed
to this domain (Liot et al., 2006; Ortiz-Zapater et al., 2007;
Correa et al., 2011; Haile et al., 2012). The EGF-like domain
has been also reported to contribute to the hepatic recapture
of tPA (Hajjar and Reynolds, 1994). The kringle domains fold
into large loops stabilized by three disulﬁde bridges. Because
of the high-mannose-type glycosylation at Asn117, K1 is of
major importance in the uptake of tPA by mannose receptors
on liver endothelial cells in vivo and in vitro (Kuiper et al.,
1996). The K2 domain and more speciﬁcally its lysine binding
site (LBS) is involved in the capacity of tPA to bind and activate
substrates and/or receptors such as plasminogen, PDGF-CC
(platelet derived growth factor-CC; Fredriksson et al., 2004) and
NMDAR (N-methyl-D-aspartate receptor; López-Atalaya et al.,
2008). The K1 of tPA does not possess a LBS (Kim et al., 2003).
The C-terminal domain supports the catalytic activity of tPA
and forms the catalytic triad (His 322, Asp 371, and Ser 478)
involving an aspartic acid residue (Asp371) hydrogen-bonded to
a histidine (His322), which itself is hydrogen-bonded to a serine
(Ser478).
As detailed here after, the literature suggests that there is not
one but several forms of tPAs.
Long and Short Variants
The pro-form of tPA is a molecule of 562 amino acids. The
signal peptide and a pro-peptide of, respectively, 22 and 10
amino acids should be removed before storage in vesicles and
release. Three additional amino acids (Gly–Ala–Arg) at the
N-terminal end of the molecule can be also removed leading to
the release of either the long variant (L-tPA) or the short variant
(S-tPA) of 530 and 527 amino acids, respectively (Jörnvall et al.,
1983; Berg and Grinnell, 1991). These tPAs include 17 disulﬁde
bridges.
sc-tPA vs. tc-tPA
In contrast to the other members of the chymotrypsin family, tPA
is not synthesized and secreted as a “true” zymogen (Madison
et al., 1993). Like other members of the family, the secreted
single-chain tPA (sc-tPA; Figure 1A) can be processed into
a two-chain form tPA (tc-tPA; Figure 1B) by plasmin or
kallikrein (Wallén et al., 1982; Ichinose et al., 1984). However,
sc-tPA is an unusually active zymogen (high intrinsic proteolytic
activity, low zymogenicity) that does not require proteolytic
processing to be active but relies on the presence of an allosteric
regulator, such as ﬁbrin (Thelwell and Longstaﬀ, 2007). The
passage from the sc-tPA to the tc-tPA form results from the
hydrolysis of the peptide bond linking the Arg275 and the
Ile276, both parts of the protein remaining connected by a
disulﬁde bridge between Cys299 (heavy chain A) and Cys430
FIGURE 1 | Schematic representations of the primary structure of
sc-tPA (A) and tc-tPA (B). Each amino acid is represented by its single letter
symbol. Sites of N- ( ) or O-glycosylation ( ) are showed. The active site
residues His322, Asp371, and Ser478 are marked by stars. The amino acids
involved in the structure of the lysine binding site are noted with asterisks. The
black bars indicate disulfide bonds. The black bar dotted indicate salt bond.
The double-arrow indicates the cleavage site for conversion of sc-tPA to
tc-tPA.
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(light chain B) and a novel salt bridge between Arg302 and
Glu445 (Lamba et al., 1996). In the absence of an allosteric
regulator such as ﬁbrin, tc-tPA is ﬁvefold catalytically more
active than sc-tPA (Rånby et al., 1982; Wallén et al., 1982;
Tate et al., 1987; Petersen et al., 1988; Boose et al., 1989).
However, in the presence of ﬁbrin, both sc-tPA and tc-tPA
display the same catalytic activity (Thelwell and Longstaﬀ,
2007).
Type I vs. Type II tPA
Type plasminogen activator is a glycoprotein containing three
major N-glycosylation sites. Two glycosylations are constitutives
at Asn117 within the kringle 1 domain and at Asn448 within
the serine protease domain. A third one is alternative at Asn184
within the kringle 2 domain. Type I tPA is glycosylated at
Asn117, Asn184, and Asn448, while type II tPA is glycosylated
only at Asn117 and Asn448 (Pohl et al., 1984; Spellman et al.,
1989; Mori et al., 1995; Jaques et al., 1996). Asn184 acts as
a switch that enables long-distance communication between
ﬁbrin-binding residues (achieved by the ﬁnger domain) and
the catalytic site in the protease domain (Rathore et al., 2012).
Glycosylation of Asn184 (i.e., type I) reduces the ability of
tPA to activate plasminogen as well as its binding to ﬁbrin
(Einarsson et al., 1985; Wittwer et al., 1989; Berg et al., 1993).
Type I sc-tPA seems to be more stable than type II sc-tPA
regarding its conversion to tc-tPA (Wittwer and Howard, 1990;
Berg et al., 1993; Figure 2). tPA also contains a O-linked fucose
at Thr61 (occupancy 100%) within the EGF domain (Harris
et al., 1991) and potentially an additional N-glycosylation site
at Asn142 within the K1 domain (occupancy 1%; Borisov et al.,
2009).
IS tPA GOOD OR BAD FOR NEURONAL
SURVIVAL?
The Facts
The group of Sidney Strickland was the ﬁrst to demonstrate
that tPA deﬁcient mice were more sensitive to hippocampal
FIGURE 2 | The diversity of tPAs. L-tPA and S-tPA are released under their
single chain form (sc-tPA), possibly cleaved into their two-chain form (tc-tPA)
by plasmin or kalikrein. Each form of tPA exists in two glycosylated states,
types I or II.
neuronal death induced by both NMDAR- and non-NMDAR-
agonists (Tsirka et al., 1995), an eﬀect dependent of the
ability of tPA to activate plasminogen into plasmin (Tsirka
et al., 1997a,b; Figure 3A). Accordingly, several studies have
reported that inhibitors of tPA, such as neuroserpin and type
1 plasminogen activator inhibitor (PAI-1) protect neurons
against toxicity induced by the over-activation of NMDARs
(Buisson et al., 1998; Zhang et al., 2002; Gabriel et al., 2003;
Lebeurrier et al., 2005). Exogenous tPA was then reported
pro-neurotoxic, on cortical neurons, in paradigms of in
vitro or in vivo excitotoxicity mediated by over-activation of
NMDAR (Nicole et al., 2001; Liberatore et al., 2003; Reddrop
et al., 2005; Park et al., 2008; Figure 3B). The tPA was
also reported to promote damages on Purkinje cells (Lu
and Tsirka, 2002; Li et al., 2006, 2013; Cops et al., 2013;
Figure 3C), especially by altering the neurotrophic mechanisms
that control their postnatal development (Li et al., 2006,
2013).
Both plasmin-dependent and plasmin-independent
mechanisms have been proposed to explain the potentiation
of NMDAR signaling by tPA (Nicole et al., 2001; Pawlak
et al., 2002; Matys and Strickland, 2003), but several recent
studies agree that it can occur independently of plasminogen
activation (Samson et al., 2008; Echeverry et al., 2010; Parcq
et al., 2012). For instance, tPA can interact with the GluN1
subunit of NMDAR involving the LBS of its K2 domain (Nicole
et al., 2001; Fernández-Monreal et al., 2004; Kvajo et al., 2004;
López-Atalaya et al., 2008; Parcq et al., 2012). Our group
reported that the cleavage of the amino-terminal domain of
GluN1 subunit is necessary for enhancement of NMDAR
signaling by tPA (Nicole et al., 2001; Fernández-Monreal et al.,
2004). In the brain of protease nexin-1 (PN-1, an inhibitor
of tPA) deﬁcient mice, Kvajo et al. (2004), demonstrated an
increase in the proteolytic activity of tPA, correlated with a
decrease in the amount of the GluN1 subunit of the NMDA
receptor. However, no cleavage of GluN1 was observed despite
the interaction of tPA with the GluN1 subunits of NMDAR
(Kvajo et al., 2004). Other groups did not detect tPA-dependent
cleavage of GluN1, despite enhancement of NMDAR function
by exogenous tPA in cortical cultures (Samson et al., 2008).
In a more recent study, it was reported that sc-tPA, but not
tc-tPA can promote NMDAR signaling and neurotoxicity in
cortical neurons (Parcq et al., 2012; Bertrand et al., 2015).
These data were the ﬁrst to describe a diﬀerential function
of sc-tPA and tc-tPA. tPA would also act on neuronal death
by engaging Low density lipoprotein related protein (LRP)
receptors, which in turn would enhance Ca2+ downstream
of NMDAR (Samson et al., 2008). More recent data obtained
from Schwann cells showed that tPA can promote NMDAR
signaling independently of LRP1 (Mantuano et al., 2015).
Similarly, in PC12 and N2a neuron-like cells, tPA may signal
through a complex containing NMDAR, LPR1, and Trk
receptors (Mantuano et al., 2013). Plasmin, which is generated
by the tPA-dependent conversion of plasminogen, has also
been reported to cleave NMDARs, speciﬁcally the GluN2
subunit. This cleavage can occur at two sites: Lys317 on
GluN2A, which relieves Zn2+ inhibition and thereby increases
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 October 2015 | Volume 9 | Article 415
Chevilley et al. tPA and neuronal survival
FIGURE 3 | Possible mechanisms of tPA on neuronal survival. (A) Hippocampal neurons; (B) cortical neurons; (C) cerebellar neurons. NSP, neuroserpin; Pln,
plasmin; PAI-1, plasminogen activator inhibitor-1; NMDAR, N-methyl-D-aspartate receptor; EGFR, epidermal growth factor receptor; KA-R, kainate receptor; A-II,
annexin II receptor.
NMDAR function (Yuan et al., 2009), and Arg67 on GluN2B,
which increases sensitivity of the NMDAR to glycine (Ng
et al., 2012). Whether tPA-dependent plasmin formation
counteracts or interferes with tPA-dependent NMDAR
activation is still under debate. Whatever the mechanism,
all these studies showed that tPA can increase NMDAR
signaling.
By contrast, other studies, in particular using transgenic mice
over-expressing tPA in neurons (T4 transgenic mice) or tPA
KO mice, suggested that tPA can also have neuroprotective
eﬀects (Haile et al., 2012; Wu et al., 2012). These two studies
also proposed a mechanism dependent on the activation of
NMDAR and independent on plasmin. In vitro and ex vivo
studies also reported pro-survival eﬀects of tPA on neurons (Liot
et al., 2006; Lee et al., 2007; Polavarapu et al., 2007; Bertrand
et al., 2015; Lemarchand et al., 2015), mainly anti-apoptotic
eﬀects. Also interesting, tPA was reported to attenuate zinc-
induced neuronal cell death independently of its proteolytic
action (Kim et al., 1999; Siddiq and Tsirka, 2004). Despite the
heterogeneity of the paradigms used in these diﬀerent studies,
they all showed that this eﬀect of tPA occurs independently of
its proteolytic activity, with the activation of either PI3K/Akt,
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AMPK- or mTor-HIF-1alpha-dependent signaling pathways
needed (Correa et al., 2011; Wu et al., 2012; Figure 3B).
Two candidates have been proposed as the receptors mediating
the pro-survival eﬀects of tPA: Annexin II and EGF receptor
(Siao and Tsirka, 2002; Wu et al., 2012; Bertrand et al., 2015;
Lemarchand et al., 2015). The ability of tPA to convert the
pro-neurotrophins (BDNF, NGF) to their active forms (Pang
et al., 2004) is also a possible explanation to the pro-survival
eﬀects of tPA.
WHAT ARE THE POSSIBLE
EXPLANATIONS OF THE DIFFERENTIAL
EFFECTS OF tPA ON NEURONAL
SURVIVAL? (TABLE 1)
Are Target Receptors the Explanations?
In the brain parenchyma, pro-survival and pro-neurotoxic eﬀects
of tPA have been shown to involve key receptors/pathways,
including NMDAR (Nicole et al., 2001), LRP-mediated PSD95
activation (Martin et al., 2008), annexin-II (Siao and Tsirka,
2002), and EGF receptor (Liot et al., 2006; Lemarchand et al.,
2015). Focusing on NMDARs, the fact that tPA induces toxic or
protective eﬀects could also depend on the diﬀerent subtypes of
GluN subunits involved, and/or their location (synaptic versus
extrasynaptic; Paoletti et al., 2013). For instance, based on
the current literature, it could be postulated that exogenous
tPA could promote neurotoxicity on cortical neurons by
activating extrasynaptic GluN2D-containing NMDARs (Baron
et al., 2010; Jullienne et al., 2011; Montagne et al., 2012),
but could lead to a neuroprotective eﬀect by activating
synaptic GluN2A-containing NMDARs (Wu et al., 2013a;
Figure 3B). Several studies also propose that the neuroprotective
activity of tPA, even in a paradigm involving NMDARs, is
NMDAR-independent (Correa et al., 2011), independent of
its proteolytic activity (Liot et al., 2006). In a model of
apoptosis induced by serum deprivation (Liot et al., 2006)
or when subjected to OGD, the neuroprotective eﬀect of tPA
is mediated by an activation of either EGFR (Correa et al.,
2011; Bertrand et al., 2015; Lemarchand et al., 2015) or
annexin II (Lee et al., 2007). Whether LRP is also involved
is still under debate, again dependent on the paradigm used
(Martin et al., 2008). Up to now, it is not clear how these
diﬀerent receptors contribute to the diﬀerential eﬀects of tPA
in neuronal survival. Additional studies are needed including
investigations about possible crosstalks between these diﬀerent
receptors.
Are Protocols of Neuronal Injury the
Explanation?
Type plasminogen activator-dependent over-activation of
NMDARs has been proposed as a mechanism that could mediate
both neuroprotective (Wu et al., 2013b) and neurotoxic (Baron
et al., 2010) eﬀects of tPA (Figure 3B). This discrepancy may
be explained by the use of diﬀerent models to induce neuronal
death, either pure NMDAR-mediated excitotoxicity (Baron et al.,
2010) or oxygen glucose deprivation (OGD; Wu et al., 2013b).
Whether OGD induces excitotoxicity and/or apoptosis is not
well documented and might depend on the severity/duration of
the stress. Pathways such as autophagy or endoplasmic reticulum
stress may also occur (Badiola et al., 2011; Shi et al., 2012).
Another explanation could be the use of diﬀerential strategies to
block tPA-induced potentiation of NMDAR signaling, MK-801
as a broad irreversible antagonist of NMDARs on one hand
(Terro et al., 2000) and an antibody previously characterized
to speciﬁcally prevent the tPA-dependent potentiation of
NMDARs signaling without aﬀecting their basal activity
(Benchenane et al., 2007; Macrez et al., 2010) on the other
hand. It is interesting to note that either over-activation and
blockage of NMDARs are neurotoxic, the ﬁrst one leading to
excitotoxic neuronal death (Nicole et al., 2001), the second one
inducing apoptosis (Mattson and Duan, 1999; Henry et al.,
2013).
Is Neuronal Maturity an Explanation?
To discuss the diﬀerential impact of tPA on neuronal survival,
how neurons are mature is also an important issue including
whether experiments were performed in vitro (neuronal cultures
performed from E16 embryo and maintained diﬀerent times
in vitro, 5–14 days (Buisson et al., 1998; Samson et al., 2008),
ex vivo (hippocampal slices harvested at P3 and maintained
diﬀerent times in vitro; Lemarchand et al., 2015) or in vivo
(young versus aged animals; Roussel et al., 2009). For example,
it was well-demonstrated that mouse primary cultures of cortical
neurons become sensitive to NMDA-induced neuronal death
only after 10 days in vitro, an eﬀect potentiated by exogenous
tPA (Launay et al., 2008). At early times (days in vitro), they
require trophic factors contained in the culture media (serum) to
survive (Hetman et al., 2000; Terro et al., 2000). When removed,
serum deprivation led to neuronal apoptosis with a protective
eﬀect of exogenous tPA (Liot et al., 2006). Type of neurons may
also be critical, with neurotoxic eﬀects of tPAmainly described in
cortical neurons (Nicole et al., 2001) or Purkinje neurons (Cops
et al., 2013; Li et al., 2013; Figures 3B,C). The protective eﬀect
of tPA was described on hippocampal neurons (Flavin and Zhao,
2001; Echeverry et al., 2010; Lemarchand et al., 2015; Figure 3A)
and on cortical neurons (Liot et al., 2006; Wu et al., 2013a;
Figure 3B).
Does the Origin of tPA (Endogenous vs.
Exogenous) make the Difference?
Another important point of discussion is to know whether
exogenous and endogenous tPA have diﬀerential eﬀects
on neuronal survival. The most recent literature in
this ﬁeld demonstrates that endogenous tPA displays
neuroprotective activities (Wu et al., 2013a; Lemarchand
et al., 2015) and exogenous tPA is neurotoxic (Parcq et al.,
2012). Nevertheless, using tPA deﬁcient mice, exogenous
tPA may also protect hippocampal neurons subjected
to OGD (Lemarchand et al., 2015). These data suggest
that tPA (exogenous or endogenous) may have either
pro-neurotoxic or pro-survival eﬀects depending of the type of
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stress paradigms used and/or the type of neurons. Thus, whether
experiments are performed on wild type neurons, tPA deﬁcient
neurons, tPA over-expressing neurons, in vitro and in vivo, is
important to understand the impacts of tPA on neuronal survival
(Tsirka et al., 1995;Wang et al., 1998; Nicole et al., 2001; Liot et al.,
2006; Echeverry et al., 2010; Wu et al., 2013a).
WHAT ABOUT THE LEVEL OF tPA?
Some authors suggest that low levels of tPA are neuroprotective
(Wu et al., 2013a), either exogenous (Baron et al., 2010) or
produced by stressed cells (Lemarchand et al., 2015). In contrast,
high levels of tPA (mainly exogenous) are neurotoxic (Nicole
et al., 2001; Parcq et al., 2012).
Finally, Why not the Form of tPA?
There is so far only one study which discriminated tPA isoforms
in the context of neuronal survival, with a clear evidence that
sc-tPA is the only one capable to activate NMDAR and to
promote excitotoxicity (in mouse cortical neurons subjected to
NMDA exposure) both in vitro and in vivo (Parcq et al., 2012;
Bertrand et al., 2015). It is thus interesting to note, that complexes
formed between sc-tPA and neuroserpin (NSP) were reported
more stable than those formed between tc-tPA and NSP, with
no diﬀerences when complexes are formed with PAI-1 (Barker-
Carlson et al., 2002). Whether conversion of sc-tPA into tc-tPA
(by plasmin like activity) may inﬂuence the functions of tPA on
neuronal survival, especially in the context of brain injuries, need
to be investigated.
CONCLUSION
Depending on the study, endogenous tPA was reported
as deleterious or beneﬁcial for neurons. Although it is
diﬃcult to reconcile these ﬁndings, some propose that tPA
is neuroprotective at low levels, but neurotoxic at higher
levels. Assays of extracellular levels of tPA under speciﬁc
conditions should be provided to support this hypothesis.
Undoubtedly, the target involved is also a key trigger in
the eﬀect of tPA. In general, the pro-survival eﬀects of
tPA are independent on its proteolytic activity involving,
interconnected or independently, EGF receptors, annexin II,
PI-3 kinase-, AMPK-, mTor-HIF-1alpha-dependent signaling
pathways. In the adult, the neurotoxic eﬀects of tPA seem
to be dependent on its proteolytic activity, targeting either
plasminogen, NMDARs, components of the extracellular matrix,
inﬂammatory mediators, and/or other proteases. However,
indirect neurotoxicity might also occur via a non-proteolytic
activation of microglia (Siao and Tsirka, 2002). For now, there
is no clear clinical data to determine, in human, whether
tPA is neurotrophic or neurotoxic and in what conditions.
Additional studies are needed to understand further the possible
diﬀerential functions of tPA on neuronal survival. To address
this question, we should consider the diﬀerent isoforms of
tPA (type I sc-tPA, type I tc-tPA, type II sc-tPA, and type
II tc-tPA), the possibility that tPA may activate its substrates
and/or receptors with diﬀerential aﬃnities and that these
substrates and/or receptors could be diﬀerentially expressed
in cortical versus hippocampal neurons depending on their
maturity.
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